Literature DB >> 16969844

Favorable effect of balloon mitral valvuloplasty on the incidence of atrial fibrillation in patients with severe mitral stenosis.

Mohamed Eid Fawzy1, Mohamed Shoukri, Hani Al Sergani, Bahaa Fadel, Abdulmoniem Eldali, Mohammed Al Amri, Charles C Canver.   

Abstract

BACKGROUND: The long-term effect of balloon mitral valvuloplasty (BMV) on the incidence of atrial fibrillation (AF) in patients with severe mitral stenosis (MS) remains undetermined. AIMS: To assess the effect of successful BMV on the incidence of chronic AF in patients with severe MS, compare the results with historical controls, and identify factors associated with AF in such patients.
METHODS: Retrospective analysis of 382 consecutive patients with severe MS and in sinus rhythm (SR) who underwent successful BMV (post procedure mitral valve area (MVA) > or =1.5 cm(2), mitral regurgitation (MR) < or =2/4) at our hospital and followed-up for 1-15.6 (mean 5.6 +/- 3.9) years with clinical and echocardiographic examination.
RESULTS: Thirty-four (8.9%) patients developed AF at follow-up (group A) and 348 patients (group B) remained in SR. At baseline, and in comparison with group B, patients who developed AF (group A) were older, had higher mitral echo score but equal MVA and left atrial (LA) size. The postprocedure MVA was smaller in group A (1.7 +/- 0.3 cm(2)) than in group B (2.0 +/- 0.2 cm(2;) P = 0.002). At follow-up, and in comparison to group B, group A had smaller MVA (1.5 +/- 0.4 cm(2) vs 1.8 +/- 0.4 cm(2) P <0.0001), larger LA dimension (49.4 +/- 6.5 vs 42 +/- 6.5 mm; P <0.0001) and higher restenosis rate (35% vs 14%; P = 0.001). Multivariate logistic regression analysis identified age at follow-up (P < 0.0001), LA size at follow-up (P = 0.004), and MVA at follow-up (P = 0.006) as predictors of AF.
CONCLUSIONS: This study demonstrated favorable effect of BMV on the incidence of AF (8.9%) in patients with severe MS in comparison with reported series (29%) of patients with severe MS with similar baseline characteristics who were not submitted to any intervention. The predictors of AF were age, larger LA, and smaller MVA, at follow-up.

Entities:  

Mesh:

Year:  2006        PMID: 16969844     DOI: 10.1002/ccd.20770

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

1.  Immediate effect of percutaneous transvenous mitral commissurotomy on atrial electromechanical delay and P-wave dispersion in patients with severe mitral stenosis.

Authors:  Jahangir Rashid Beig; Nisar A Tramboo; Hilal A Rather; Imran Hafeez; Vijai Ananth; Ajaz A Lone; Irfan Yaqoob; Irfan A Bhat; Muzaffar Ali
Journal:  Indian Heart J       Date:  2015-11-21

2.  Sinus Rhythm in Rheumatic Mitral Stenosis after Balloon Mitral Valvotomy: Is it Feasible?

Authors:  Ashwal A Jayaram; Anand N Shukla; Saurin Shah; Vidya Nayak; Sridevi Prabhu; Umesh Pai
Journal:  J Clin Diagn Res       Date:  2017-02-01

3.  Mitral balloon valvuloplasty.

Authors:  Mohamed Eid Fawzy
Journal:  J Saudi Heart Assoc       Date:  2010-05-11

4.  The acute effect of percutaneous mitral balloon valvuloplasty on atrial electromechanical delay and P-wave dispersion in patients with mitral stenosis.

Authors:  B Demirkan; Y Guray; U Guray; M R Ege; H L Kisacik; H Sasmaz; S Korkmaz
Journal:  Herz       Date:  2012-09-08       Impact factor: 1.443

5.  Immediate And Long Term Effects Of Percutaneous Mitral Balloon Valvuloplasty On Atrial Conduction Velocities In Patients With Mitral Stenosis.

Authors:  Hicaz Zencirkiran Agus; Serkan Kahraman; Begum Uygur; Arda Guler; Gokhan Demirci; Ali Kemal Kalkan; Mehmet Erturk; Mustafa Yildiz
Journal:  J Atr Fibrillation       Date:  2019-02-28

6.  Usefulness of the Macruz Index for Predicting Successful Percutaneous Mitral Balloon Valvuloplasty in Patients with Mitral Stenosis.

Authors:  Kevser Gülcihan Balcı; Mustafa Mücahit Balcı; Orhan Maden; Fatih Şen; Mehmet Kadri Akboga; Burak Açar; Meryem Kara; Sadık Kadri Açıkgöz; Hatice Selcuk; Mehmet Timur Selcuk
Journal:  Med Princ Pract       Date:  2015-11-06       Impact factor: 1.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.